Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene.
OBJECTIVE
After radiation therapy for prostate cancer, approximately 50% of the patients experience acute genitourinary symptoms, mostly nocturia. This may be highly bothersome with a major impact on the patient's quality of life. In the past, nocturia is seldom reported as a single, physiologically distinct endpoint, and little is known about its etiology. It is assumed that in addition to dose-volume parameters and patient- and therapy-related factors, a genetic component contributes to the development of radiation-induced damage. In this study, we investigated the association among dosimetric, clinical, and TGFβ1 polymorphisms and the development of acute radiation-induced nocturia in prostate cancer patients.


METHODS
Data were available for 322 prostate cancer patients treated with primary or postoperative intensity modulated radiation therapy (IMRT). Five genetic markers in the TGFβ1 gene (-800 G>A, -509 C>T, codon 10 T>C, codon 25 G>C, g.10780 T>G), and a high number of clinical and dosimetric parameters were considered. Toxicity was scored using an symptom scale developed in-house.


RESULTS
Radical prostatectomy (P<.001) and the presence of pretreatment nocturia (P<.001) are significantly associated with the occurrence of radiation-induced acute toxicity. The -509 CT/TT (P=.010) and codon 10 TC/CC (P=.005) genotypes are significantly associated with an increased risk for radiation-induced acute nocturia.


CONCLUSIONS
Radical prostatectomy, the presence of pretreatment nocturia symptoms, and the variant alleles of TGFβ1 -509 C>T and codon 10 T>C are identified as factors involved in the development of acute radiation-induced nocturia. These findings may contribute to the research on prediction of late nocturia after IMRT for prostate cancer.
Department of Basic Medical Sciences, Ghent University, Gent, Belgium. Sofie.DeLanghe@UGent.be
Sofie
S
De Langhe
Kim
K
De Ruyck
Piet
P
Ost
Valérie
V
Fonteyne
Joke
J
Werbrouck
Gert
G
De Meerleer
Wilfried
W
De Neve
Hubert
H
Thierens
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000726:Androgen Antagonists / Q000627:therapeutic use; D003062:Codon / Q000235:genetics; D005819:Genetic Markers; D006801:Humans; D008297:Male; D008875:Middle Aged; D053158:Nocturia / Q000209:etiology* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy* / Q000601:surgery*; D011832:Radiation Injuries / Q000150:complications*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D053773:Transforming Growth Factor beta1 / Q000235:genetics*
D000726:Androgen Antagonists; D003062:Codon; D005819:Genetic Markers; D053773:Transforming Growth Factor beta1